A Study of a Single Dose of ALXN1210 in Healthy Participants
A Phase 1, Randomized, Blinded, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of ALXN1210 Administered Intravenously to Healthy Subjects
Study Complete
Study Details
Medical Condition
Study Phase
Intervention Type
Product
DateMedical ConditionRequirement Information
Date
AgeDateParticipation Requirements
Inclusion Criteria
Exclusion CriteriaInclusion CriteriaThis study evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single dose of ALXN1210 in healthy participants, as assessed by electrocardiograms, physical examination, vital signs, laboratory analysis, and assessment of adverse events (AEs).
| Location | Status |
|---|---|
Location Canada Clinical Trial Site Montréal, Canada | Status Not Available |
